NEW YORK (dpa-AFX) – Statements from the latest US Federal Reserve minutes encouraged investors on Wednesday. However, caution and restraint continued to determine trading. The indices increased only moderately.
Der Wall Street Index Dow Jones Industrial it rose about an hour and a half before close of trading by 0.56 percent to 29,402.18 points and thus slightly widened its small lead over the previous day. The S&P 500 , which had indirectly fluctuated between plus and minus in the previous hours, like the Nasdaq, recently rose 0.35 percent to 3601.40 points. The Nasdaq 100 Technology Index increased by 0.59 percent to 10,855.37 points.
While the Fed believes monetary tightening to combat high inflation is still appropriate “for some time,” it has also been pointed out that a slower tightening would be appropriate at some point. However, many central bankers are still of the opinion that the costs of a too timid fight against inflation are likely to outweigh those of too hard a fight against inflation, according to the (minute) minutes of the half-year interest rate meeting. September. During the meeting, the Fed drastically raised the benchmark interest rate by 0.75 percentage points for the third consecutive time.
Bank shares rose after the Fed minutes. So did JPMorgan shares at the top of the Dow, up 2.1%. In the S&P 100 Morgan Stanley shares won Goldman Sachs
US Bancorp, Bank of America and Wells Fargo between 0.7 and 1.9 per cent.
In the Dow were the shares of the aircraft manufacturer Boeing
Down with minus 1.2 percent, while Coca-Cola
was one of the favorites with a plus of 1.7%. These latter papers benefited from unexpectedly strong quarterly data from competitor Pepsico . The management of the drinks and snacks giant has again raised its indications for the year after a positive third quarter. Pepsico increased by 4.2%.
Shares of vaccine maker Covid 19 Moderna have settled in the Nasdaq selection index upward. Sometimes over 17 percent, they have increased more than they were in about two months. Most recently, they gained 8.7%. The pharmaceutical company Merck & Co previously announced that it would exercise an option to collaborate with biotechnology on a messenger RNA cancer vaccine. Moderna will receive $ 250 million from Merck in exchange for co-development and future commercialization of the vaccine. This is currently in the mid-stage of clinical trials, according to a statement from the two companies. / Ck / he
ISIN US2605661048 XC0009694271 US6311011026 US78378X1072
AXC0348 2022-10-12 / 20: 40
Copyright dpa-AFX business news GmbH. All rights reserved. Redistribution, republication or permanent storage is not permitted without the prior express consent of dpa-AFX.
